However, although these targets are all expressed on AML LSC (CD44, CD47, CD157) and/or CML LSC (CD26, CD44, CD47, CD56), clinical application, when tested in AML, resulted only in minor or transient effects on neoplastic cells [99,100,102]. The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.